236 related articles for article (PubMed ID: 23956349)
21. Penetrance of functioning and nonfunctioning pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 in the second decade of life.
Gonçalves TD; Toledo RA; Sekiya T; Matuguma SE; Maluf Filho F; Rocha MS; Siqueira SA; Glezer A; Bronstein MD; Pereira MA; Jureidini R; Bacchella T; Machado MC; Toledo SP; Lourenço DM
J Clin Endocrinol Metab; 2014 Jan; 99(1):E89-96. PubMed ID: 24178797
[TBL] [Abstract][Full Text] [Related]
22. Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1.
Thomas-Marques L; Murat A; Delemer B; Penfornis A; Cardot-Bauters C; Baudin E; Niccoli-Sire P; Levoir D; Choplin Hdu B; Chabre O; Jovenin N; Cadiot G;
Am J Gastroenterol; 2006 Feb; 101(2):266-73. PubMed ID: 16454829
[TBL] [Abstract][Full Text] [Related]
23. Clinical usefulness of plasma chromogranin a in pancreatic neuroendocrine neoplasm.
Paik WH; Ryu JK; Song BJ; Kim J; Park JK; Kim YT; Yoon YB
J Korean Med Sci; 2013 May; 28(5):750-4. PubMed ID: 23678268
[TBL] [Abstract][Full Text] [Related]
24. Initiating Pancreatic Neuroendocrine Tumor (pNET) Screening in Young MEN1 Patients: Results From the DutchMEN Study Group.
Klein Haneveld MJ; van Treijen MJC; Pieterman CRC; Dekkers OM; van de Ven A; de Herder WW; Zandee WT; Drent ML; Bisschop PH; Havekes B; Vriens MR; Verrijn Stuart AA; Valk GD; van Leeuwaarde RS
J Clin Endocrinol Metab; 2021 Nov; 106(12):3515-3525. PubMed ID: 34333645
[TBL] [Abstract][Full Text] [Related]
25. The predictive value of mean platelet volume in differential diagnosis of non-functional pancreatic neuroendocrine tumors from pancreatic adenocarcinomas.
Karaman K; Bostanci EB; Aksoy E; Kurt M; Celep B; Ulas M; Dalgic T; Surmelioglu A; Hayran M; Akoglu M
Eur J Intern Med; 2011 Dec; 22(6):e95-8. PubMed ID: 22075321
[TBL] [Abstract][Full Text] [Related]
26. Management of pancreatic neuroendocrine tumors.
Dabizzi E; Panossian A; Raimondo M
Minerva Gastroenterol Dietol; 2010 Dec; 56(4):467-79. PubMed ID: 21139544
[TBL] [Abstract][Full Text] [Related]
27. Preoperative assessment of the pancreas in multiple endocrine neoplasia type 1.
Lewis MA; Thompson GB; Young WF
World J Surg; 2012 Jun; 36(6):1375-81. PubMed ID: 22382771
[TBL] [Abstract][Full Text] [Related]
28. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.
Modlin IM; Drozdov I; Alaimo D; Callahan S; Teixiera N; Bodei L; Kidd M
Endocr Relat Cancer; 2014 Aug; 21(4):615-28. PubMed ID: 25015994
[TBL] [Abstract][Full Text] [Related]
29. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.
Han X; Zhang C; Tang M; Xu X; Liu L; Ji Y; Pan B; Lou W
Eur J Gastroenterol Hepatol; 2015 May; 27(5):527-35. PubMed ID: 25822862
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
31. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
Lawrence B; Gustafsson BI; Kidd M; Pavel M; Svejda B; Modlin IM
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):111-34, viii. PubMed ID: 21349414
[TBL] [Abstract][Full Text] [Related]
32. Are biochemical markers of neuroendocrine tumors coreleased with insulin following local calcium stimulation in patients with insulinomas?
Wiesli P; Uthoff H; Perren A; Pfammatter T; Zwimpfer C; Seiler H; Kindhauser R; Spinas GA; Schmid C
Pancreas; 2011 Oct; 40(7):995-9. PubMed ID: 21705951
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic value of chromogranin A in pancreatic neuroendocrine tumors depends on tumor size: A prospective observational study from a single institute.
Jun E; Kim SC; Song KB; Hwang DW; Lee JH; Shin SH; Hong SM; Park KM; Lee YJ
Surgery; 2017 Jul; 162(1):120-130. PubMed ID: 28262254
[TBL] [Abstract][Full Text] [Related]
34. Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors.
Jensen KH; Hilsted L; Jensen C; Mynster T; Rehfeld JF; Knigge U
Scand J Gastroenterol; 2013 Jan; 48(1):70-7. PubMed ID: 23094948
[TBL] [Abstract][Full Text] [Related]
35. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors.
Shanahan MA; Salem A; Fisher A; Cho CS; Leverson G; Winslow ER; Weber SM
J Surg Res; 2016 Mar; 201(1):38-43. PubMed ID: 26850182
[TBL] [Abstract][Full Text] [Related]
36. Serum pancreastatin: the next predictive neuroendocrine tumor marker.
Rustagi S; Warner RR; Divino CM
J Surg Oncol; 2013 Aug; 108(2):126-8. PubMed ID: 23775817
[TBL] [Abstract][Full Text] [Related]
37. Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas.
Goebel SU; Serrano J; Yu F; Gibril F; Venzon DJ; Jensen RT
Cancer; 1999 Apr; 85(7):1470-83. PubMed ID: 10193936
[TBL] [Abstract][Full Text] [Related]
38. Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas.
Qiao XW; Qiu L; Chen YJ; Meng CT; Sun Z; Bai CM; Zhao DC; Zhang TP; Zhao YP; Song YL; Wang YH; Chen J; Lu CM
BMC Endocr Disord; 2014 Aug; 14():64. PubMed ID: 25099181
[TBL] [Abstract][Full Text] [Related]
39. Reliability and Agreement of Radiological and Pathological Tumor Size in Patients with Multiple Endocrine Neoplasia Type 1-Related Pancreatic Neuroendocrine Tumors: Results from a Population-Based Cohort.
van Beek DJ; Verkooijen HM; Nell S; Bonsing BA; van Eijck CH; van Goor H; Hoogwater FJH; Nieveen van Dijkum EJM; Kazemier G; Dejong CHC; Brosens LAA; Wessels FJ; Borel Rinkes IHM; Valk GD; Vriens MR
Neuroendocrinology; 2021; 111(8):705-717. PubMed ID: 32721974
[TBL] [Abstract][Full Text] [Related]
40. Baseline plasma chromogranin A levels in patients with well-differentiated neuroendocrine tumors of the pancreas: A potential predictor of postoperative recurrence.
Nanno Y; Toyama H; Matsumoto I; Otani K; Asari S; Goto T; Ajiki T; Zen Y; Fukumoto T; Ku Y
Pancreatology; 2017; 17(2):291-294. PubMed ID: 28043759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
